ABPOOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as ABPWW
Abpro Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.41+0.00 (+0.11%)
Close on Oct 19, 2026
- Market cap
- $2.41M
- P/E (TTM)
- –
- Dividend yield
- –
Abpro Holdings, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2024 | FY2023 | % of revenue | YoY |
|---|---|---|---|---|
| Research and development [Member] | $183.00K | – | 100.0% | – |
| Royalty | – | $23.00K | – | – |
| Collaboration revenue | – | $99.00K | – | – |
By region
From the segment and revenue-disaggregation notes of Abpro's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.